Latest BMEA news

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Benzinga · Wed, 23 Sep 2026 14:12:42 -0400

Biomea Fusion, Inc. (NASDAQ:BMEA) shares are trading lower by almost 19% on Wednesday as investors digest the company's decision to terminate its proposed public offering.

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

GlobeNewsWire · Wed, 23 Sep 2026 07:03:00 -0400

SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. No securities were sold in connection with the proposed offering.

Biomea Fusion Announces Proposed Public Offering of Securities

GlobeNewsWire · Tue, 22 Sep 2026 16:05:00 -0400

SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are to be sold by Biomea.

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

Zacks Investment Research · Fri, 04 Sep 2026 11:15:59 -0400

Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Biomea Fusion to Participate in Upcoming Investor Conferences

GlobeNewsWire · Thu, 03 Sep 2026 08:00:00 -0400

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.

Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

Benzinga · Mon, 24 Aug 2026 16:05:59 -0400

Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

GlobeNewsWire · Mon, 24 Aug 2026 07:00:00 -0400

SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-deficient T2D who remain inadequately controlled on standard-of-care antihyperglycemic therapies.

Market information is provided for research and visualization and is not investment advice.